Cargando…

A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice

Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Jiang, Peizhao, Song, Tao, Yang, Keli, Yuan, Fangyan, Gao, Ting, Liu, Zewen, Li, Chang, Guo, Rui, Xiao, Shaobo, Tian, Yongxiang, Zhou, Danna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457768/
https://www.ncbi.nlm.nih.gov/pubmed/37631860
http://dx.doi.org/10.3390/vaccines11081291
_version_ 1785097003861016576
author Liu, Wei
Jiang, Peizhao
Song, Tao
Yang, Keli
Yuan, Fangyan
Gao, Ting
Liu, Zewen
Li, Chang
Guo, Rui
Xiao, Shaobo
Tian, Yongxiang
Zhou, Danna
author_facet Liu, Wei
Jiang, Peizhao
Song, Tao
Yang, Keli
Yuan, Fangyan
Gao, Ting
Liu, Zewen
Li, Chang
Guo, Rui
Xiao, Shaobo
Tian, Yongxiang
Zhou, Danna
author_sort Liu, Wei
collection PubMed
description Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industry. Cellular immunity plays a key role in the prevention and control of porcine enzootic pneumonia. Therefore, the development of a more efficient vaccine that confers a strong immunity against M. hyopneumoniae is necessary. In this study, a multi-antigen chimera (L9m6) was constructed by combining the heat-labile enterotoxin B subunit (LTB) with three antigens of M. hyopneumoniae (P97R1, mhp390, and P46), and its immunogenic and antigenic properties were assessed in a murine model. In addition, we compared the effect of individual administration and multiple-fusion of these antigens. The chimeric multi-fusion vaccine induced significant cellular immune responses and high production of IgG and IgM antibodies against M. hyopneumoniae. Collectively, our data suggested that rL9m6 chimera exhibits potential as a viable vaccine candidate for the prevention and control of porcine enzootic pneumonia.
format Online
Article
Text
id pubmed-10457768
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104577682023-08-27 A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice Liu, Wei Jiang, Peizhao Song, Tao Yang, Keli Yuan, Fangyan Gao, Ting Liu, Zewen Li, Chang Guo, Rui Xiao, Shaobo Tian, Yongxiang Zhou, Danna Vaccines (Basel) Article Mycoplasma hyopneumoniae is the etiological agent of porcine enzootic pneumonia (EP), leading to a mild and chronic pneumonia in swine. Relative control has been attained through active vaccination programs, but porcine enzootic pneumonia remains a significant economic challenge in the swine industry. Cellular immunity plays a key role in the prevention and control of porcine enzootic pneumonia. Therefore, the development of a more efficient vaccine that confers a strong immunity against M. hyopneumoniae is necessary. In this study, a multi-antigen chimera (L9m6) was constructed by combining the heat-labile enterotoxin B subunit (LTB) with three antigens of M. hyopneumoniae (P97R1, mhp390, and P46), and its immunogenic and antigenic properties were assessed in a murine model. In addition, we compared the effect of individual administration and multiple-fusion of these antigens. The chimeric multi-fusion vaccine induced significant cellular immune responses and high production of IgG and IgM antibodies against M. hyopneumoniae. Collectively, our data suggested that rL9m6 chimera exhibits potential as a viable vaccine candidate for the prevention and control of porcine enzootic pneumonia. MDPI 2023-07-28 /pmc/articles/PMC10457768/ /pubmed/37631860 http://dx.doi.org/10.3390/vaccines11081291 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Liu, Wei
Jiang, Peizhao
Song, Tao
Yang, Keli
Yuan, Fangyan
Gao, Ting
Liu, Zewen
Li, Chang
Guo, Rui
Xiao, Shaobo
Tian, Yongxiang
Zhou, Danna
A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title_full A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title_fullStr A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title_full_unstemmed A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title_short A Recombinant Chimera Vaccine Composed of LTB and Mycoplasma hyopneumoniae Antigens P97R1, mhp390 and P46 Elicits Cellular Immunologic Response in Mice
title_sort recombinant chimera vaccine composed of ltb and mycoplasma hyopneumoniae antigens p97r1, mhp390 and p46 elicits cellular immunologic response in mice
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457768/
https://www.ncbi.nlm.nih.gov/pubmed/37631860
http://dx.doi.org/10.3390/vaccines11081291
work_keys_str_mv AT liuwei arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT jiangpeizhao arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT songtao arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT yangkeli arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT yuanfangyan arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT gaoting arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT liuzewen arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT lichang arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT guorui arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT xiaoshaobo arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT tianyongxiang arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT zhoudanna arecombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT liuwei recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT jiangpeizhao recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT songtao recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT yangkeli recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT yuanfangyan recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT gaoting recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT liuzewen recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT lichang recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT guorui recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT xiaoshaobo recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT tianyongxiang recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice
AT zhoudanna recombinantchimeravaccinecomposedofltbandmycoplasmahyopneumoniaeantigensp97r1mhp390andp46elicitscellularimmunologicresponseinmice